X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

Content Team by Content Team
14th February 2022
in Packaging & Logistic, Press Statements
Envirotainer introduces the RAP for the future - part of the Releye series

Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, launched its latest innovation, the Releye® RAP. This is complemented by the new Control Tower managed service.

The Releye® RAP sets a new benchmark for temperature-controlled 5-pallet solutions. The largest of the new generation Releye® containers, the RAP is the only one of its type in the world, combining big capacity with superior features.

Designed to meet the strictest requirements in pharmaceutical air freight, the integrated live monitoring enables a unique insight into product condition, location and progress of the shipment.

With its increased efficiency and capacity, it reaches outstanding CO2 reductions per shipment, and is the future solution for secure cold chain shipments. All monitored and maintained with the new service Control Tower.

The Releye® RAP is the second in a family of advanced temperature-controlled air freight containers Envirotainer is developing. It joins the 3-pallet Releye® RLP launched in 2021. The foundation of the Releye® platform are the five pillars: Control, Monitoring, Autonomy, Value and Sustainability.

More Value, More Sustainability

Because the Releye® RAP offers the largest internal volume for temperature-controlled air freight shipments, it makes more efficient use of available air cargo capacity. This offers the best value Total Landed Cost and achieves the lowest CO2 footprint in the air cargo industry.

Quite simply, it offers the most cargo space per fuel unit and has the smallest CO2 footprint of all solutions on the market. This is thanks to its low weight, large cargo space and outstanding reliability.
Easy Qualification?

The beauty of the Releye® RAP is that it is based on exactly the same platform and technology as the Releye® RLP. Thanks to this and the comprehensive data made available, the additional qualification of a Releye® unit is the easiest in the cold chain industry and requires marginal effort from our customers and partners.

Control Tower

The Envirotainer Control Tower service offers a global team of operators to follow a shipment’s every move, ready to respond within minutes to any critical event. The Envirotainer Control Tower service is included with all Releye® leases.

Swiss WorldCargo, the leading carrier in intensive care pharmaceutical shipments, is the first European carrier to approve the Releye® RAP container for their operations and to add it to their portfolio.

“We really appreciate our close partnership with Envirotainer and are proud to be the first European carrier to approve the new Envirotainer Releye® RAP and to welcoming it into our product portfolio,” said Lorenzo Stoll, Head of Cargo at Swiss International Air Lines. “The Releye® RAP sets a new benchmark for temperature-controlled 5-pallet solutions, it combines newest technology and reaches outstanding CO2 reductions per shipment. This fully aligns with our own focus on sustainable operations and continued reduction of our carbon footprint.”

“When we launched the new Releye® RLP in May 2021, we raised the bar in cold chain transportation to new heights of Control, Monitoring and Autonomy. Now, with the launch of Releye® RAP, we raise the bar yet another notch in terms of Value and Sustainability”, says Peter Gisel-Ekdahl, CEO at Envirotainer.

“The COVID-19 pandemic is ongoing. Air cargo capacity is constrained and there’s a huge demand for intercontinental shipments. In this context, organisations that qualify the Releye® RAP will secure access to the most cost-efficient and sustainable solution for temperature-controlled airfreight,” says Fredrik Linnér, Chief Business Development Officer at Envirotainer.

“The Releye® series offer unique visibility, and with the Control Tower service, we’re taking visibility to another level. Based on the most sophisticated Live Monitoring technology in the market, and our 24/7/365 customer service, we are monitoring all Releye® shipments, offering our customers a helping hand within 15 minutes from any potential event happening, in order to secure the safe delivery of pharmaceuticals,” says Linus Wollentz, Head of Digital Services at Envirotainer

About Envirotainer

Envirotainer is the undisputed global market leader in secure cold chain solutions?for air transport of pharmaceuticals. The company develops, manufactures and offers leasing of innovative container solutions, including validation, support and service, for pharma products that require a controlled environment. Thanks to a truly global presence with the world’s largest active container fleet, the most extensive network and more than 35 years of industry expertise, Envirotainer is able to meet the customers’ need for innovative and reliable solutions – available from any location to any destination. The company operates through an open, global network of airlines and forwarders and the headquarters is located outside of Stockholm, Sweden.

Previous Post

Opticooler receives technical approval by Japanese major airlines

Next Post

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

Related Posts

ACHEMA 2022 addresses the industry's key issues digitalisation and sustainability
Manufacturing

ACHEMA 2022 addresses the industry’s key issues digitalisation and sustainability

14th June 2022
development of new antibiotics
Drug Development

EMA guidance supports development of new antibiotics

30th May 2022
Vienna Airport and Lufthansa Cargo launch pharma cooperation
Packaging & Logistic

Vienna Airport and Lufthansa Cargo launch pharma cooperation

10th May 2022
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
Drug Development

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

6th May 2022
Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility
Press Statements

Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility

6th May 2022
AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint
Drug Development

AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

6th May 2022
Next Post
NIH begins study of allergic reactions to Covid-19 vaccines

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In